Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial

被引：0
|
作者：
Lipton, Richard B. [1 ]
Ashina, Messoud [2 ]
Tassorelli, Cristina [3 ]
Martin, Vincent [4 ]
Yu, Sung Y. [5 ]
Nagy, Krisztian [6 ]
Schwefel, Brittany [7 ]
Trugman, Joel [5 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] Univ Copenhagen, Dept Neurol, Danish Headache Ctr, Rigshospitalet Glostrup, Cophenhagen, Denmark
[3] C Mondino Fdn & Univ Pavia, Headache Sci Ctr, Pavia, Italy
[4] Univ Cincinnati, Cincinnati, OH USA
[5] AbbVie, Madison, NJ USA
[6] AbbVie, Budapest, Hungary
[7] AbbVie, N Chicago, IL USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-EP-
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [41] Responder Rates With Eptinezumab Over 24 Weeks in Patients With Prior Migraine Preventive Treatment Failures
    Ashina, Messoud
    Lipton, Richard B.
    Ailani, Jessica
    Versijpt, Jan
    Sacco, Simona
    Mitsikostas, Dimos D.
    Christoffersen, Cecilie
    Sperling, Bjorn
    Ettrup, Anders
    NEUROLOGY, 2023, 100 (17)
  • [42] Daily atogepant provides a rapid onset and sustained benefit in the preventive treatment of migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 119 - 119
  • [43] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
  • [44] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 160
  • [45] OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine
    Chen, Shih-Pin
    Fuh, Jong-Ling
    Wang, Shuu-Jiun
    CURRENT PAIN AND HEADACHE REPORTS, 2011, 15 (01) : 4 - 7
  • [46] OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine
    Shih-Pin Chen
    Jong-Ling Fuh
    Shuu-Jiun Wang
    Current Pain and Headache Reports, 2011, 15 : 4 - 7
  • [47] Fremanezumab for the Preventive Treatment of Chronic Migraine
    Silberstein, Stephen D.
    Dodick, David W.
    Bigal, Marcelo E.
    Yeung, Paul P.
    Goadsby, Peter J.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2113 - 2122
  • [48] Impact of Atogepant on Migraine-Specific QoL Among Individuals With Episodic Migraine and Preventive Treatment Failure
    Tassorelli, C.
    Gandhi, P.
    Sacco, S.
    Pozo-Rosich, P.
    Lanteri-Minet, M.
    Nezadal, T.
    Trugman, J.
    Luo, L.
    Stokes, J.
    Nagy, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 214 - 215
  • [49] Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial
    Ashina, Messoud
    Tepper, Stewart J.
    Reuter, Uwe
    Blumenfeld, Andrew M.
    Hutchinson, Susan
    Xia, Jing
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    HEADACHE, 2023, 63 (01): : 79 - 88
  • [50] Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 163 - 163
12345